• Home
  • About OPEN
    • OPEN Foundation
    • Objectives
    • Annual Reports
      • 2011 (pdf)
      • 2010 (pdf)
      • 2009 (pdf)
  • Activities
    • Agenda
    • Overview
    • Mind Altering Science
    • Ayahuasca Symposium
    • ICPR 2012
  • Psychedelics
    • Publications
      • Recent publications
      • By substance
        • 2C-B
        • Ketamine
        • 5-MeO-DMT
        • LSD
        • Ayahuasca
        • MDA
        • DMT
        • MDMA
        • DOB
        • Mescaline
        • DOI
        • Psilocybin
        • DOM
        • Salvinorin A
      • By field
        • Anthropology
        • Psychiatry
        • Chemistry
        • Psychology
        • History
        • Psychopharmacology
        • Medicine
        • Sociology
        • Neuroscience
      • By subject
        • Addiction
        • Depression
        • Altered perception
        • Mystical experiences
        • Anxiety disorder
        • Novel substances
        • Cluster headache
        • PTSD
        • Creativity
        • Safety
    • Videotheque
      • OPEN Videos
      • Documentaries
    • Library
      • Recent book releases
      • Freely available e-books
    • Links
      • Research
      • Informative
      • Databases
      • Politics
      • Other links
  • Support us
    • Donate
    • Volunteer
  • Webshop
  • Contact
     
     
     
     
     
     

Response of cluster headache to psilocybin and LSD

The authors interviewed 53 cluster headache patients who had used psilocybin or lysergic acid diethylamide (LSD) to treat their condition. Twenty-two of 26 psilocybin users reported that psilocybin aborted attacks; 25 of 48 psilocybin users and 7 of 8 LSD users reported cluster period termination; 18 of 19 psilocybin users and 4 of 5 LSD users reported remission period extension. Research on the effects of psilocybin and LSD on cluster headache may be warranted.

R. Andrew Sewell, John H. Halpern and Harrison G. Pope, Jr.; "Response of cluster headache to psilocybin and LSD"; NEUROLOGY 2006;66:1920–1922; 10.1212/01.wnl.0000219761.05466.43.

Read pdf

Select your language

OPEN Agenda

MAY
28

28.05.2013 - 02.06.2013
Science and Nonduality Conference - The Science and Mystery of Perception

JUN
04

04.06.2013 20:00 - 23:30
OPEN borrel - East of Eden

Full agenda

Recent publications

Hallucinogen persisting perception disorder: what do we know after 50 years?

Abstract 'Flashbacks' following use of hallucinogenic drugs have been reported for decades; they are recognized in DSM-IV as 'Hallucinogen Persisting Perception Disorder (Flashbacks)', or HPPD. We located...

A possibly sigma-1 receptor mediated role of dimethyltryptamine in tissue protection, regeneration, and immunity

Abstract N,N-dimethyltryptamine (DMT) is classified as a naturally occurring serotonergic hallucinogen of plant origin. It has also been found in animal tissues and regarded as an endogenous trace amine...

In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin 2A Receptor Binding in MDMA and Hallucinogen Users

Context: Both hallucinogens and 3,4-methylenedioxy-methamphetamine (MDMA or “ecstasy”) have direct agonistic effects on postsynaptic serotonin 2A receptors, the key site for hallucinogenic actions....

The NMDA antagonist ketamine and the 5-HT agonist psilocybin produce dissociable effects on structural encoding of emotional face expressions

Rationale Both glutamate and serotonin (5-HT) play a key role in the pathophysiology of emotional biases. Recent studies indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine...
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8

User Panel

  • Forgot your password?
  • Forgot your username?
  • Create an account